
STERIS (STE) Stock Forecast & Price Target
STERIS (STE) Analyst Ratings
Bulls say
Steris is a leader in contract sterilization, healthcare equipment, and life sciences services with a strong start to FY27 driven by 6% organic growth and increased equipment orders, backlog, and HC service sales. With a $600M investment in a North Carolina facility and a new share buyback program, Steris is well positioned to drive sustainable margin expansion and a targeted 10% ROIC while managing macro volatility. However, potential risks include sensitivity to procedure volumes, supply chain and inflationary pressures, and lumpiness of capital equipment buying.
Bears say
Steris is expected to experience modest growth in all segments, but the negative impact of divesting its dental products business has not yet been fully reflected in its financials. Additionally, the company's recent inversion to Ireland raises concerns about potential tax implications and legal complications. Furthermore, the slight increase in capex and decrease in FCF guidance indicate potential financial strain in the coming year.
This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.
STERIS (STE) Analyst Forecast & Price Prediction
Start investing in STERIS (STE)
Order type
Buy in
Order amount
Est. shares
0 shares